Anti-mGlu5 blocking peptide
Discontinued ProductAnti-mGlu5 blocking peptide (Cat. No. 2102) has been withdrawn from sale for commercial reasons.
Synthetic peptide ([K]-SSPKYDTLIIRDYTQSSSSL) corresponding to the C-terminal amino acids 1184-1203 of rat precursor mGlu5 (Accession No. P31424) with a lysine added at the N-terminus of the peptide for conjugation. Immunogen used for anti-mGlu5 (Cat. No. 2032).
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
View Related Products by Target
Keywords: Anti-mGlu5 blocking peptide, Anti-mGlu5 blocking peptide supplier, Blocking, peptides, anti-mGlu5, mGluR5, Group, I, Receptors, Glutamate, Metabotropic, immunogen, (Metabotropic), 2102, Tocris Bioscience
Citations for Anti-mGlu5 blocking peptide
Citations are publications that use Tocris products.
Currently there are no citations for Anti-mGlu5 blocking peptide.
Reviews for Anti-mGlu5 blocking peptide
There are currently no reviews for this product. Be the first to review Anti-mGlu5 blocking peptide and earn rewards!
Have you used Anti-mGlu5 blocking peptide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.